11:08 AM EST, 11/05/2024 (MT Newswires) -- Merus (MRUS) said Tuesday the US Food and Drug Administration has extended the Prescription Drug User Fee Act objective deadline for experimental NRG1+ cancer treatment zenocutuzumab.

The regulator moved the deadline to Feb. 4 to allow more time to review recent information Merus submitted, the company said.

Price: 51.25, Change: +0.02, Percent Change: +0.03